profit from every ₹100 of sales.
₹0₹100
Akums Drugs AND Pharma L
₹765.85+2.96% today
+77.9% in 1 year
1-year low ₹419.701-year high ₹823.30
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹45.95 for every ₹1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Akums Drugs AND Pharma L sold, what it kept, and what it did with the cash.
Sales went from ₹34.7 billion in 2023 to ₹43.6 billion in 2026, with ₹2.55 billion of profit last year.
SalesProfit
Akums Drugs AND Pharma L vs. similar companies
Akums Drugs AND Pharma L grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Akums Drugs AND Pharma L | 45.9× · Expensive | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.6× · Expensive |
AI analysis
An AI analyst reads Akums Drugs AND Pharma L's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 34,748 | 40,197 | 41,182 | 43,590 | |
| 11,673 | 14,375 | 16,847 | 18,455 | |
| 1,913 | 3,599 | 3,072 | 3,675 | |
| 3,091 | 1,306 | 5,333 | 6,307 | |
| 949 | -40 | 3,382 | 2,552 | |
| 6.03 | -0.28 | 22.60 | – | |
| 33.6% | 35.8% | 40.9% | 42.3% | |
| 5.5% | 9.0% | 7.5% | 8.4% | |
| 2.7% | -0.1% | 8.2% | 5.9% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 32,665 | 35,164 | 41,134 | 54,470 |
| Cash | 516 | 1,111 | 1,012 | 3,860 |
| Total debt | 6,191 | 5,652 | 882 | 1,574 |
| Total liabilities | 25,432 | 27,959 | 10,498 | 21,158 |
| 7,172 | 7,095 | 30,470 | 33,133 | |
| 157 | 157 | 150 | – | |
| 11.0% | 0.3% | 9.1% | 10.3% | |
| 13.2% | -0.6% | 11.1% | 7.7% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 1,766 | 4,983 | 4,652 | 11,812 | |
| 3,288 | 3,114 | 2,723 | 2,305 | |
| -1,522 | 1,869 | 1,929 | 9,507 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| – | – | – | – |
Valuation
- 45.9×
- –
- –
- 2.8×
- 2.7×
- 12.3×
- 18.2×
- 8.1%
- 2.2%
- –
Profitability
- 42.3%
- 8.4%
- 5.9%
- –
- 10.3%
- 7.7%
- –
- –
- –
- –
Growth
- +7.9%
- –
- –
- –
- −1.7%
Financial health
- -0.4×
- 0.05
- –
- 5.1×
- 3.25
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 27%of 948
Bottom 49%of 871
Bottom 26%of 560
Bottom 38%of 868
Top 10%of 985
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
45No pass
Benjamin Graham
33No pass
Philip Fisher
38No pass
Peter Lynch
54No pass
Joel Greenblatt
17No pass
Charlie Munger
40No pass
Terry Smith
33No pass
Questions about Akums Drugs AND Pharma L
Is Akums Drugs AND Pharma L a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Akums Drugs AND Pharma L AI analysis
What does Akums Drugs AND Pharma L do?
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. It is in Drug Manufacturers - Specialty & Generic, based in Delhi, India.
Is Akums Drugs AND Pharma L stock halal?
Yes. Akums Drugs AND Pharma L passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has Akums Drugs AND Pharma L stock done over the past year?
Up 77.9% over the past twelve months, to ₹765.85. It traded between ₹419.70 and ₹823.30 and is 7.0% below its high.
Who are Akums Drugs AND Pharma L's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Akums Drugs AND Pharma L's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.